News | November 10, 2025
Marksans Pharma's Goa unit clears FDA inspection
The said inspection concluded with Zero Form 483 observation
The said inspection concluded with Zero Form 483 observation
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Relmada expects to initiate its Phase 3 program in the first half of 2026
Poviztra is a second brand of Wegovy
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Subscribe To Our Newsletter & Stay Updated
